Swiss National Bank
ESPR

Swiss National Bank’s Esperion Therapeutics ESPR Stock Holding History

Swiss National Bank’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-172,500
Closed -$274K – 2621
2023
Q1 		$274K Buy
172,500
+35,900
+26% +$185K ﹤0.01% 2619
2022
Q4 		$851K Buy
+136,600
New +$977K ﹤0.01% 2420
2021
Q4 		– Sell
-52,400
Closed -$631K – 2732
2021
Q3 		$631K Hold
52,400
– – ﹤0.01% 2546
2021
Q2 		$1.11M Sell
52,400
-8,100
-13% -$195K ﹤0.01% 2439
2021
Q1 		$1.7M Buy
60,500
+1,000
+2% +$29.5K ﹤0.01% 2100
2020
Q4 		$1.55M Hold
59,500
– – ﹤0.01% 2061
2020
Q3 		$2.21M Buy
59,500
+1,600
+3% +$63.4K ﹤0.01% 1669
2020
Q2 		$2.97M Buy
57,900
+10,200
+21% +$427K ﹤0.01% 1476
2020
Q1 		$1.5M Buy
47,700
+900
+2% +$47.5K ﹤0.01% 1622
2019
Q4 		$2.79M Buy
46,800
+1,500
+3% +$67.4K ﹤0.01% 1534
2019
Q3 		$1.66M Buy
45,300
+400
+0.9% +$15.8K ﹤0.01% 1767
2019
Q2 		$2.09M Buy
44,900
+900
+2% +$42.3K ﹤0.01% 1666
2019
Q1 		$1.77M Buy
44,000
+1,300
+3% +$58.3K ﹤0.01% 1740
2018
Q4 		$1.96M Buy
42,700
+1,200
+3% +$57.8K ﹤0.01% 1585
2018
Q3 		$1.84M Hold
41,500
– – ﹤0.01% 1767
2018
Q2 		$1.63M Buy
41,500
+5,600
+16% +$283K ﹤0.01% 1841
2018
Q1 		$2.6M Buy
35,900
+1,600
+5% +$117K ﹤0.01% 1466
2017
Q4 		$2.26M Hold
34,300
– – ﹤0.01% 1570
2017
Q3 		$1.72M Buy
34,300
+8,000
+30% +$386K ﹤0.01% 1712
2017
Q2 		$1.22M Buy
26,300
+4,100
+18% +$151K ﹤0.01% 1921
2017
Q1 		$784K Hold
22,200
– – ﹤0.01% 2176
2016
Q4 		$278K Hold
22,200
– – ﹤0.01% 2522
2016
Q3 		$307K Hold
22,200
– – ﹤0.01% 2481
2016
Q2 		$219K Buy
22,200
+1,500
+7% +$24.9K ﹤0.01% 2554
2016
Q1 		$338K Buy
20,700
+4,200
+25% +$67.6K ﹤0.01% 2460
2015
Q4 		$367K Hold
16,500
– – ﹤0.01% 2404
2015
Q3 		$389K Buy
16,500
+2,200
+15% +$138K ﹤0.01% 2307
2015
Q2 		$1.17M Buy
14,300
+1,600
+13% +$157K ﹤0.01% 1701
2015
Q1 		$1.18M Buy
12,700
+4,300
+51% +$278K ﹤0.01% 1677
2014
Q4 		$340K Buy
+8,400
New +$257K ﹤0.01% 2354

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Swiss National Bank's ESPR Position: Q2 2023 in Review

Swiss National Bank sold out of Esperion Therapeutics (ESPR) in Q2 2023, closing a stake of 172,500 shares — an estimated $274K sold.

Swiss National Bank first reported a position in ESPR in Q4 2014 and held it in 30 quarters. The position peaked at $2.97M in Q2 2020. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

  • Swiss National Bank reported no remaining Esperion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Swiss National Bank sold 172,500 Esperion Therapeutics shares in Q2 2023, an estimated $274K.
  • Swiss National Bank first reported a position in Esperion Therapeutics in Q4 2014 and held it in 30 quarters.
  • Swiss National Bank's Esperion Therapeutics position peaked at $2.97M in Q2 2020.
  • 124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Swiss National Bank's 13F filing for Q2 2023, filed 9 Aug 2023.